151751-Najiba-Chargi

345 Systemic therapy: skeletal muscle mass and functional outcomes Appendix 11. Baseline characteristics stratified by pretreatment sarcopenia. P values shown for Mann- Whitney U test a , linear-by-linear approximation of the Pearson’s Chi-square test b or Fisher’s exact Test c . No sarcopenia N = 59 Sarcopenia N = 49 P value Other 6 (10) 10 (20) T classification T1 19 (32) 8 (16) .031 b T2 16 (27) 14 (29) T3 16 (27) 13 (27) T4 8 (14) 14 (29) N classification N0 8 (14) 4 (8) .287 b N1 15 (25) 9 (18) N2 34 (58) 35 (71) N3 2 (3) 1 (20 AJCC stage III 20 (34) 8 (16) . 048 c IV 39 (66) 41 (84) HPV Negative 14 (25) 19 (41) .090 c Positive 43 (75) 27 (59) Unknown 2 3 Treatment modality RT 27 (46) 12 (24) .090 b RT unfit for chemo 0 (0) 3 (6) CRT (cetuximab) 9 (15) 8 (16) CRT (cisplatin) 23 (39) 26 (53) Modified diet at t 0 (FOIS < 7) No 53 (90) 36 (74) . 041 c Yes 6 (10) 13 (27) Trismus at t 0 No 54 (96) 44 (92) .411 c Yes 2 (4) 4 (8) Unknown 3 1 NB: Not all percentages sum up exactly to 100% due to rounding. Abbreviations: BMI = body mass index, CRT = chemoradiotherapy (cisplatin or cetuximab based), HPV = human papilloma virus, other = soft palate, uvula, oropharyngeal wall, vallecula or pharyngeal arch, RT = radiotherapy, sarcopenia = skeletal muscle mass below 43.2 cm 2 /m 2 . 17